Literature DB >> 15297959

Borderline ovarian tumors: key points and workshop summary.

Steven G Silverberg1, Debra A Bell, Robert J Kurman, Jeffrey D Seidman, Jaime Prat, Brigitte M Ronnett, Larry Copeland, Elvio Silva, Fred Gorstein, Robert H Young.   

Abstract

This article documents major points of agreement and disagreement among experts invited to participate in a Borderline Ovarian Tumor Workshop held in Bethesda, MD, on August 27-28, 2003. It is suggested that controversies related to the diagnosis and management of these tumors are often related to lack of data in the literature (small numbers of cases, unreported or unclear criteria for diagnosis and follow-up, insufficient length of follow-up, etc), and specific recommendations are made for further investigation and for reporting of data in future studies.

Entities:  

Mesh:

Year:  2004        PMID: 15297959     DOI: 10.1016/j.humpath.2004.03.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.

Authors:  Qin Zhu; Yuqing Qu; Qiongyan Zhang; Linghui Lu; Weiwei Weng; Hao Zhang; Lihong Zhang; Yan Ning; Yiqin Wang
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Authors:  Kruti P Maniar; Yihong Wang; Kala Visvanathan; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

Review 3.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

Review 4.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

Review 5.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

6.  A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass.

Authors:  Wouter Wegdam; Perry D Moerland; Danielle Meijer; Shreyas M de Jong; Huub C J Hoefsloot; Gemma G Kenter; Marrije R Buist; Johannes Mf G Aerts
Journal:  Proteome Sci       Date:  2012-07-23       Impact factor: 2.480

Review 7.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

8.  Histologic distribution of borderline ovarian tumors worldwide: a systematic review.

Authors:  Taejong Song; Yoo-Young Lee; Chel Hun Choi; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

9.  Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor.

Authors:  Margarita Romeo; Francesc Pons; Pilar Barretina; Joaquim Radua
Journal:  World J Surg Oncol       Date:  2013-01-23       Impact factor: 2.754

10.  External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours.

Authors:  S Bendifallah; C Uzan; R Fauvet; P Morice; E Darai
Journal:  Br J Cancer       Date:  2013-10-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.